Even before the coronavirus pandemic underscored the critical need for life sciences real estate, Taylor Johnson client CA Ventures saw opportunity in the fast-growing sector. In February, the Chicago-based real estate investment management company announced the launch of a new medical office and life sciences division and its plans to invest approximately $500 million per year through development and value-add acquisitions across the U.S. So, when National Real Estate Investor was looking for sources to comment on the future of life sciences real estate, we connected the publication with Russell Brenner, president of CA’s new division. In the resulting article, Brenner explained why R&D assets are expected to remain an investor favorite despite the economic challenges created by COVID-19. Read more here.

In a recent interview with National Real Estate Investor, Russell Brenner, president of CA Ventures’ new medical office and life sciences division, explained why the long-term outlook for life sciences real estate remains favorable.